Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients with previously untreated diffuse large B-cell lymphoma (DLBCL) Extended follow-up data from EPCORE® NHL-1 trial demonstrates durability of responses and long-term safety of epcoritamab monotherapy for patients with challenging-to-treat relapsed/refractory (R/R) DLBCL Both analyses were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) Genmab A/S (NASDAQ:GMAB) today announced new long-term results from two ongoing clinical tri

Genmab A/S (NASDAQ:GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with epcoritamab The data were selected as part of the 2024 American Society of Hematology's (ASH's) Annual Meeting Press Program in the Diagnosing and Treating Blood Cancers and "Almost Cancers" briefing Genmab A/S (

Genmab A/S (NASDAQ:GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results follow recent breakthrough therapy designation (BTD) granted by U.S. Food and Drug Administration (FDA) and support ongoing Phase 3 EPCORE® FL-1 trial evaluating epcoritamab + R2 in patients with R/R FL Genmab A/S (NASDAQ:GMAB)

  Genmab A/S (NASDAQ:GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patients New and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (NASDAQ:GMAB) announced today more than 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's lymphoma (NHL) subtypes, will be presented at the 66th Annual Meeting and Exposition of t

Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world. Genmab receives royalties on the worldwide

ProfoundBio co-founders Dr. Baiteng Zhao and Dr. Tae H. Han recognized for building the state's most valuable life science company in less than a decade Life Science Washington Institute (LSWI), a Life Science Washington affiliate focused on supporting early-stage companies and entrepreneurs in Washington state, today announced Baiteng Zhao, PhD, and Tae H. Han, PhD, co-founders of ProfoundBio, as the recipients of the 2024 Entrepreneurial Achievement Award. Launched in 2020, this award honors founding leaders who have demonstrated significant entrepreneurial accomplishments, advanced life-changing innovations, and contributed to Washington state's economic development. This press release

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.   About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative a

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m2 in patients with advanced ovarian cancer Genmab A/S (NASDAQ:GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 wee

Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy Genmab A/S (NASDAQ:GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for

Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (NASDAQ:GMAB) today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated biotech innovation powerhouse. Genmab's Executive Committee will include Rayne Waller in the newly created role of Executive Vice President and Chief Technology Officer and Brad Bailey in the newly created role of Executive Vice President and Chief Commercial Officer. Execu

SC 13G/A - GENMAB A/S (0001434265) (Subject)

SC 13G/A - GENMAB A/S (0001434265) (Subject)

SC 13G - GENMAB A/S (0001434265) (Subject)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

6-K - GENMAB A/S (0001434265) (Filer)

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumors Genmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark and SEATTLE, Washington; April 3, 2024 – Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have

Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for 2024. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investors. Conference CallGenmab will hold a conference call in English to discuss the full year results for 2023 today, February 14, 2024 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive

Company Announcement COPENHAGEN, Denmark; March 2, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 41,574 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 600 shares at DKK 31.75,21,690 shares at DKK 40.41,125 shares at DKK 55.85,300 shares at DKK 220.40,1,000 shares at DKK 225.30,73 shares at DKK 815.50,3,563 shares at DKK 939.50,10,005 shares at DKK 1,032.00,250 shares at DKK 1,136.00,3,176 shares at DKK 1,145.00,300 shares at DKK 1,233.00,367 shares at DKK 1,

Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

Redburn Atlantic initiated coverage of Genmab with a rating of Buy

Morgan Stanley resumed coverage of Genmab with a rating of Equal-Weight and set a new price target of $31.00

JP Morgan downgraded Genmab from Overweight to Neutral

RBC Capital Mkts upgraded Genmab from Sector Perform to Outperform

BMO Capital Markets upgraded Genmab from Market Perform to Outperform and set a new price target of $48.00 from $46.00 previously

Citigroup downgraded Genmab from Neutral to Sell

UBS upgraded Genmab from Neutral to Buy

Deutsche Bank upgraded Genmab from Hold to Buy

DNB Markets upgraded Genmab from Sell to Buy

Exane BNP Paribas initiated coverage of Genmab with a rating of Underperform